Showing 1 - 7 of 7 Items
Showing 1 - 7 of 7 Items
Sort By: Relevance
Journal Article
|Research
2024-04-15 • Journal of Acquired Immune Deficiency Syndromes (JAIDS)
2024-04-15 • Journal of Acquired Immune Deficiency Syndromes (JAIDS)
INTRODUCTION
People living with HIV are considered at higher risk of developing severe forms of tuberculosis (TB) disease. Providing HIV testing to TB-exposed people is therefore cri...
People living with HIV are considered at higher risk of developing severe forms of tuberculosis (TB) disease. Providing HIV testing to TB-exposed people is therefore cri...
Journal Article
|Research
2024-03-01 • Journal of Acquired Immune Deficiency Syndromes (JAIDS)
2024-03-01 • Journal of Acquired Immune Deficiency Syndromes (JAIDS)
OBJECTIVES
Efforts to control the COVID-19 pandemic have potentially compromised the availability and/or quality of HIV services. We aimed to assess the pandemic’s impact on ART init...
Efforts to control the COVID-19 pandemic have potentially compromised the availability and/or quality of HIV services. We aimed to assess the pandemic’s impact on ART init...
Journal Article
|Research
2024-03-01 • Journal of Acquired Immune Deficiency Syndromes (JAIDS)
2024-03-01 • Journal of Acquired Immune Deficiency Syndromes (JAIDS)
BACKGROUND
Tenofovir diphosphate (TFV-DP) concentration in dried blood spots is a marker of long-term adherence. We investigated the relationship between TFV-DP concentrations and vi...
Tenofovir diphosphate (TFV-DP) concentration in dried blood spots is a marker of long-term adherence. We investigated the relationship between TFV-DP concentrations and vi...
Journal Article
|Research
2023-09-28 • Journal of Acquired Immune Deficiency Syndromes (JAIDS)
2023-09-28 • Journal of Acquired Immune Deficiency Syndromes (JAIDS)
OBJECTIVES
The Covid-19 pandemic’s impact on initiation and effectiveness of antiretroviral therapy (ART) in people diagnosed with HIV remains unclear. We evaluated critical delays i...
The Covid-19 pandemic’s impact on initiation and effectiveness of antiretroviral therapy (ART) in people diagnosed with HIV remains unclear. We evaluated critical delays i...
Journal Article
|Research
2019-12-01 • Journal of Acquired Immune Deficiency Syndromes (JAIDS)
2019-12-01 • Journal of Acquired Immune Deficiency Syndromes (JAIDS)
BACKGROUND
Residual systemic inflammation, which is associated with non-AIDS clinical outcomes, may persist despite viral suppression. We assessed the effect of antiretroviral therap...
Residual systemic inflammation, which is associated with non-AIDS clinical outcomes, may persist despite viral suppression. We assessed the effect of antiretroviral therap...
Journal Article
|Research
2011-03-01 • Journal of Acquired Immune Deficiency Syndromes (JAIDS)
2011-03-01 • Journal of Acquired Immune Deficiency Syndromes (JAIDS)
BACKGROUND
The latest World Health Organization guidelines recommend replacing stavudine with tenofovir or zidovudine in first-line antiretroviral therapy in resource-limited setting...
The latest World Health Organization guidelines recommend replacing stavudine with tenofovir or zidovudine in first-line antiretroviral therapy in resource-limited setting...
Journal Article
|Research
2021-12-15 • Journal of Acquired Immune Deficiency Syndromes (JAIDS)
2021-12-15 • Journal of Acquired Immune Deficiency Syndromes (JAIDS)
BACKGROUND
The lack of acute and early HIV infection (AEHI) diagnosis and care contributes to high HIV incidence in resource-limited settings. We aimed to assess the yield, predict a...
The lack of acute and early HIV infection (AEHI) diagnosis and care contributes to high HIV incidence in resource-limited settings. We aimed to assess the yield, predict a...